Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. - Wikidata - awgldk - TriplyDB

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.

http://www.wikidata.org/entity/Q38305006

about

The fate of chemoresistance in triple negative breast cancer (TNBC)Beyond taxanes: the next generation of microtubule-targeting agents The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes Approaching solid tumor heterogeneity on a cellular basis by tissue proteomics using laser capture microdissection and biological mass spectrometry P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents.End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents Ligand-receptor interaction between triterpenoids and the 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2) enzyme predicts their toxic effects against tumorigenic r/m HM-SFME-1 cells Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action.A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy.Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance 2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance.The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis.Development of a rapid and sensitive UPLC-MS/MS assay for the determination of TM-2 in beagle dog plasma and its application to a pharmacokinetic study.Synthesis and biological activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents.Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone.Lentinan exerts synergistic apoptotic effects with paclitaxel in A549 cells via activating ROS-TXNIP-NLRP3 inflammasome Novel water-soluble substituted pyrrolo[3,2-d]pyrimidines: design, synthesis, and biological evaluation as antitubulin antitumor agents Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.Altered TUBB3 expression contributes to the epothilone response of mitotic cells.Circadian variations in rat liver gene expression: relationships to drug actions.Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel Modelling the microtubule: towards a better understanding of short-chain fatty acid molecular pharmacology.Epothilones in the treatment of ovarian cancer.Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?Tubulin: an example of targeted chemotherapy.Design, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3-d]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Cells.Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin.Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer.Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.

P2860

Q26775232-07835BF7-FC9B-43E7-8333-AA1424DF6B60 Q26865369-1AFBACDC-DAFE-4739-ACEB-094D903C1846 Q27010233-637CD9EB-27E9-48F1-8E9C-F7C165B9C30D Q27851983-CD827202-D36C-4BD4-A7DD-00A2ED6EFA3A Q28244659-C90D07BA-4C6D-4F8D-9232-BEDF411165FE Q28475393-617F845F-DB5B-43E2-9118-155F8C94E955 Q33418010-0FDF4EE4-2F0F-4D2F-8E5E-77910B2604B7 Q33472987-F4FEE77E-5065-4ACA-A86C-02B0BD89C92A Q33630855-32CF3800-DA62-47A1-8300-50321A795ACE Q33632830-62F071DF-FD89-4A8C-AF9C-CE46FC473C64 Q33829740-B648EF0D-B84D-4843-A293-276ED5FFA5CA Q33872751-26DD9229-0882-47DA-BA37-CA5162AD2D3A Q34006732-E5475768-7A86-4F3A-8661-9D2EC00F9B3D Q34069298-BF32346E-C9DD-4485-ABEC-ED387BFE1233 Q34266467-E0B0EA62-D11F-4E42-9098-1C66EE8807B5 Q34274930-34AC6BBA-FCB2-4DBF-851C-287DEEF6D0A9 Q34336551-12D6F304-9E85-4736-9F08-AE1CC92D4261 Q35110635-8EF0C6FD-1D97-4F0A-A8EE-2960D6F2E5F0 Q35140489-5578E1B7-F6F4-4F1E-B62D-55E271E939CE Q35168711-1CBF1E5A-A51E-4B44-83FE-4C82583DFD84 Q35253350-3449AEAF-8E4D-47AC-AB4E-1FB6EB488ED3 Q35975007-C2CBEC97-464D-4586-8B8B-2C356FEF4A04 Q35995102-36DA73E0-48B8-44A6-AD62-D8BCA4BADFBB Q36328577-22AB23EC-F18D-44FC-9077-CD8CF2787DB6 Q36388185-A92CD00E-BA3D-470D-B901-65E4997EBDC1 Q36411072-C3167C13-98AB-47BB-A7DC-2CCAD28FCE4D Q36557893-E33500C5-55C8-4AC8-ACCB-D408D62BD3AF Q36923742-2B66505A-96C0-429A-BFFF-8B6946F6C5CE Q36980135-D2121D78-F537-4D72-92E4-AD1052746518 Q37038455-2C46572D-E109-4463-9735-386E4AD103FB Q37570220-F42F55E5-0B16-4B63-9F31-F21FC4D98C78 Q37625835-CEF789BC-973A-41EA-8B35-75E39411BE56 Q37833936-158AE8EE-72E6-4625-AF14-601970C72D2D Q37861204-DC5D56D7-53E1-48C4-B8C5-DD609B3401EC Q38069185-F035BF6D-8E13-4CE4-9F89-9BD163A97BB9 Q38086872-DB1D4610-0FC5-4A4D-A32D-81F6A7E9E9C6 Q38769177-27D12B43-3C3A-419E-979C-FFFB7D44E4D3 Q38810389-B50394EA-BFA9-4C19-9EFD-E2D323249D3A Q38832323-E5722CAC-C898-4C3F-8D1A-15B909402D2B Q38922208-DC13783A-FB69-45F9-947B-554B4F4B42A2

P2860

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.

http://www.wikidata.org/entity/Q38305006

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.

@en

type

label

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.

@en

prefLabel

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.

@en

P1433

Q38305006-27991EBB-C92B-4874-9BE4-E10F85C7C6D1

P1476

Q38305006-A9BB0149-E48A-4F7C-93E7-B395F90FFD6A

P2093

Q38305006-065F1477-B0FB-4E57-A9BE-26B614EBDE84

Q38305006-09F818E2-9FE6-4995-95BA-086068AC2F95

Q38305006-3A117AF7-711E-4A0E-AA46-60B82E4F53E3

Q38305006-466C89EC-3C85-45D9-8D18-C1E3D1F024B9

Q38305006-481B9969-AF64-43AC-B611-759221074BC9

Q38305006-89DBB15E-48A6-437C-BA70-0ADBC9FA6CA2

Q38305006-A8869BCE-9F65-4F5D-B55B-A12AB56E27A3

Q38305006-A8D10D29-5C7C-401F-BC32-A3E0E453B955

Q38305006-BA5AFEF4-1656-4161-8711-AD70A5428D34

Q38305006-BE2A4D3F-912D-4758-A4F5-9B4D6EF6407C

P2860

Q38305006-08398112-A84A-4B80-B475-A0F7FA795C9B

Q38305006-0D26C8C2-5554-4793-A1E6-99FA368548ED

Q38305006-141A8462-751B-42D1-BECD-EF863F0E3CF8

Q38305006-1F24DE94-7AF0-4128-895D-6550B023DB0A

Q38305006-24060D92-7E50-439D-8260-D47BD4414C02

Q38305006-32F53F0E-9645-490F-9AC4-8BB9F7ADDC0F

Q38305006-37671ED1-E710-4AD7-8E46-440BA4964DB9

Q38305006-3A7E0679-C0A4-4024-ACC5-38206EFE2AFB

Q38305006-3A81C229-0CD6-44F2-9C39-808293309BC3

Q38305006-3FDB2BC9-DB17-41D9-BE35-0EDCF6EEC531

P304

Q38305006-31848102-7642-4D29-B124-88B5481B3710

P31

Q38305006-EA3069C0-7ACA-4ED0-B44E-EA2A6A3301F0

P356

Q38305006-8888E9AD-8C24-45D0-8A23-92615BD8AA9B

P433

Q38305006-92BE0539-24BD-47FE-B181-5F639EB9DB84

P478

Q38305006-566D2291-2903-4E42-842D-E8FC4E112A76

P50

Q38305006-2028F771-84E5-4353-AF8D-17B50C09799C

Q38305006-57C20876-5D03-4B9C-8017-60555BE261B1

P577

Q38305006-24C05A69-B5BF-474F-A431-0C68919F6463

P5875

Q38305006-180FB4D4-5D6B-45C5-A03A-FE1CEF4A802B

P698

Q38305006-A8B8965F-462E-4B64-B16E-7399ADB336D9

P921

Q38305006-13CCF148-6C06-4DC3-BDA8-C56EF21063B8

P356

P1433

International Journal of Cancer

P1476

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.

@en

P2093

Agnese Latorre

http://www.w3.org/2001/XMLSchema#string

Angelo Paradiso

http://www.w3.org/2001/XMLSchema#string

Annalisa Chiriatti

http://www.w3.org/2001/XMLSchema#string

Antonia Bellizzi

http://www.w3.org/2001/XMLSchema#string

Christopher Thomssen

http://www.w3.org/2001/XMLSchema#string

Francesco Schittulli

http://www.w3.org/2001/XMLSchema#string

Francesco Zito

http://www.w3.org/2001/XMLSchema#string

Maria Kavallaris

http://www.w3.org/2001/XMLSchema#string

Nancy Kendzierski

http://www.w3.org/2001/XMLSchema#string

Rosanna Lacalamita

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of the alpha beta tubulin dimer by electron crystallography

Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells

Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics.

A lineage-restricted and divergent beta-tubulin isoform is essential for the biogenesis, structure and function of blood platelets.

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.

Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells

p53-independent apoptosis induced by paclitaxel through an indirect mechanism.

Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol

Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance.

P304

2078-2085

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.22557

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

Stefania Tommasi

P577

2007-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6518376

http://www.w3.org/2001/XMLSchema#string

P698

17285590

http://www.w3.org/2001/XMLSchema#string

P921